Camac Fund discloses 5.3% Cryo-Cell stake
Rhea-AI Filing Summary
Camac Fund and related entities disclosed a 5.3% stake in Cryo-Cell International, Inc. common stock on a Schedule 13D. They report beneficial ownership of 430,900 shares, acquired for approximately $1,354,672, based on 8,055,150 shares outstanding as stated in Cryo-Cell’s Form 10-K for the period ended November 30, 2026.
The position was purchased with working capital and is held through Camac Fund, with Camac Partners, Camac Capital and Eric Shahinian sharing voting and dispositive power. The investors state they believed the shares were undervalued and may increase or decrease their holdings or use hedging strategies over time.
The group describes itself as active, indicating plans to periodically review the investment and potentially engage with Cryo-Cell’s management, Board, other stockholders and third parties on topics such as Board composition and corporate governance, spending levels, monetization of company assets and return of capital to shareholders.
Positive
- None.
Negative
- None.
Insights
13D shows a new 5.3% activist-style holder in Cryo-Cell.
Camac Fund and affiliated entities report owning 430,900 Cryo-Cell shares, or 5.3% of the common stock, bought for about $1,354,672. Crossing 5% and filing a Schedule 13D instead of 13G signals an active investment approach rather than a purely passive stake.
The filing states the group saw the stock as undervalued and may trade around the position or hedge exposure. More importantly, they may engage with management and the Board on governance, spending, asset monetization and returning capital. Any concrete proposals would appear in future company or investor communications.
The impact will depend on whether Camac pushes for Board changes, strategic reviews or capital actions, and how other shareholders respond. For now, this establishes an organized shareholder with meaningful influence but no specific restructuring or transaction plan disclosed in the excerpt.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake did Camac Fund disclose in Cryo-Cell International (CCEL)?
How much did Camac Fund pay for its Cryo-Cell (CCEL) position?
Why did Camac Fund file a Schedule 13D on Cryo-Cell (CCEL)?
Who are the reporting persons in the Cryo-Cell (CCEL) Schedule 13D?
What governance or strategic topics might Camac raise at Cryo-Cell (CCEL)?
AI-generated analysis. How Rhea-AI works. Not financial advice.